O

Ondine Biomedical Inc
LSE:OBI

Watchlist Manager
Ondine Biomedical Inc
LSE:OBI
Watchlist
Price: 9.25 GBX -5.13% Market Closed
Market Cap: 41m GBX

Ondine Biomedical Inc
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ondine Biomedical Inc
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
O
Ondine Biomedical Inc
LSE:OBI
Selling, General & Administrative
-CA$9.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Selling, General & Administrative
-$3.7m
CAGR 3-Years
32%
CAGR 5-Years
13%
CAGR 10-Years
-1%
Profound Medical Corp
TSX:PRN
Selling, General & Administrative
-$23.1m
CAGR 3-Years
-9%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
Nanalysis Scientific Corp
XTSX:NSCI
Selling, General & Administrative
-CA$12.4m
CAGR 3-Years
-23%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Selling, General & Administrative
-CA$2m
CAGR 3-Years
-3%
CAGR 5-Years
9%
CAGR 10-Years
0%
MedMira Inc
XTSX:MIR
Selling, General & Administrative
-CA$2.4m
CAGR 3-Years
-15%
CAGR 5-Years
-12%
CAGR 10-Years
5%

Ondine Biomedical Inc
Glance View

Market Cap
41m GBX
Industry
Health Care

Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.

OBI Intrinsic Value
4.32 GBX
Overvaluation 53%
Intrinsic Value
Price
O

See Also

What is Ondine Biomedical Inc's Selling, General & Administrative?
Selling, General & Administrative
-9.8m CAD

Based on the financial report for Dec 31, 2023, Ondine Biomedical Inc's Selling, General & Administrative amounts to -9.8m CAD.

What is Ondine Biomedical Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 1Y
20%

Over the last year, the Selling, General & Administrative growth was 20%.

Back to Top